Comparison of the results of short-term treatment showed that those patients with a CD4 cell count of 200–350 cells/mm3 at diagnosis and initial treatment showed the highest success rate of 63.1%, followed by patients with a VL of < 55,000 copies/mL and no anemia at baseline (59.9%). The gene discussed is CD4; the disease is anemia.